Search results for " biobetter"
Article
The Bullish Outlook for Biosimilars
Branded biologic manufacturers have been swift in moving to safeguard their market share by launching upgrades to their off-patent biologics called biobetters. Following traditional product-line exten…
Article
The Future of Biopharma
Biosimilars (and biobetters) are driving trends as well. With more than 700 biosimilars/biobetters in the development pipeline, there will be many more biopharmaceutical manufacturers and products, pe…
Article
State of the Biopharmaceutical Industry: Lessons from 2018 Survey Data
And this is besides it also tracking nearly 600 biobetter products at various stages. In the coming years, we expect much increased biosimilars in the market, with competition expected to bring discou…
Article
N-Glycan Analysis of Biotherapeutic Proteins
… of the biopharmaceutical market, a trend that is set to continue with the advent of biosimilars and biobetters (3, 4). N-Glycosylation, where glycans are attached to the nitrogen side chain of aspar…
Article
The Future of Biopharma
In this article, Günter Jagschies, former Senior Director, Strategic Consumer Relations at Cytiva, highlights the evolution of the biopharma industry. Günter discuss challenges and opportunities for…
Article
A Diverse Landscape of Patent Issues Seen in the US, UK, and the EU
New developments were seen in the area of biosimilars and biobetters in the United States, the UK, and the Netherlands. Sharing insights into intellectual property (IP) protection challenges on both s…
Article
Outsourcing Trends in Biopharmaceutical Manufacturing
It’s possible that a slim majority of biosimilars and biobetters will be manufactured by CMOs.
Trend five: Budgets for outsourcing are rebounding
The data and trends point to an outsourcing in…